Holen Sie sich die Stockscreener-App
24.62
7.60%
1.74
Handel nachbörslich:
25.00
0.38
+1.54%
Mineralys Therapeutics Inc Aktie (MLYS) Neueste Nachrichten
Mineralys reports 2025 results, advances hypertension drug review - MSN
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer By Investing.com - Investing.com Australia
Biopharma Co. Gives New CLO $3.6 Million In Stock Awards - Law360
Mineralys Therapeutics grants inducement equity awards to two new employees - MSN
Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer - TipRanks
Mineralys Grants Inducement Equity Awards to New Employee - MyChesCo
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer - citybiz
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer - Investing.com
Mineralys Therapeutics appoints Jeffrey A. Munsie as chief legal officer - marketscreener.com
Mineralys brings in veteran biotech lawyer as it advances lorundrostat - Stock Titan
Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA AcceptanceWhat's Changed - simplywall.st
Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Earnings Beat: Whats the profit margin of Mineralys Therapeutics IncQuarterly Risk Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Growth Value: What is the implied volatility of Mineralys Therapeutics Inc2026 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? - Yahoo Finance
Mineralys (MLYS) Q4 2025 Earnings Call Transcript - AOL.com
Why Mineralys Therapeutics Shares Are Sliding Today - TipRanks
Research Analysts Issue Forecasts for MLYS Q1 Earnings - MarketBeat
Rodman David Malcom sells Mineralys Therapeutics (MLYS) stock for $10,696 - Investing.com Canada
Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan
Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares - Stock Titan
Mineralys Reports 2025 Results, Advances Hypertension Drug Review - MyChesCo
Risk Check: Will Mineralys Therapeutics Inc outperform tech stocksTrade Volume Report & Growth-Oriented Investment Plans - baoquankhu1.vn
HC Wainwright Has Positive Outlook of MLYS FY2029 Earnings - MarketBeat
Holocene Advisors LP Buys Shares of 1,205,377 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics MLYS CMO sells shares worth $542,973 By Investing.com - Investing.com Canada
Mineralys Therapeutics CMO Sells Over 20,000 Shares - TradingView
Mineralys targets December 2026 lorundrostat approval as payer engagement and data drive launch strategy - MSN
Mineralys (MLYS) CMO exercises options, sells 20,406 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Mineralys hire gets stock options and RSUs vesting over four years - Stock Titan
Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety - TipRanks
HighVista Strategies LLC Boosts Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Farallon Capital Management LLC Purchases Shares of 1,673,053 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Cinctive Capital Management LP Has $2.72 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients - MSN
Boothbay Fund Management LLC Increases Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. $MLYS Shares Sold by 22NW LP - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Upgraded to Hold at Wall Street Zen - MarketBeat
Losartan Side Effects You Shouldn’t Ignore—Plus One That May Actually Help - AOL.com
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Suvretta Capital Management LLC - MarketBeat
Integral Health Asset Management LLC Lowers Stake in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (MLYS) makes progress with FDA for hypertension - MSN
Mineralys Therapeutics Charts Path After NDA Acceptance - TipRanks
Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026 - Meyka
David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026 - Stock Titan
Jefferies cuts Mineralys Therapeutics price target on drug concerns - Investing.com UK
Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension - Insider Monkey
Jefferies cuts Mineralys Therapeutics price target on drug concerns By Investing.com - Investing.com Australia
Mineralys Therapeutics price target raised to $51 from $46 at BofA - TipRanks
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):